      Document 0098
 DOCN  DRG0098
 UNIQUE IDENTIFIER        DRG-0149
 NAME OF SUBSTANCE        Saccharomyces boulardii [AmFAR Tx Dir
                          1995;7(4)]
 PROTOCOL ID NUMBERS      FDA 083A
 SECONDARY SOURCE ID      SB-250 [FDA 083A]
 PHARMACOLOGICAL ACTION   MODE OF ACTION: Mechanism of action is
                          unclear. In the prevention and treatment of
                          Clostridium difficile-associated diarrhea and
                          colitis S. boulardii may reduce some of the
                          enterotoxic effects of toxin A by inhibiting
                          toxin A-receptor binding. This effect appears
                          to be manifested by a secreted product of the
                          yeast, possibly a protease. [AmFAR Tx Dir
                          1995;7(4)] [Gastroenterology 1993 Apr;104(4)]
 DISEASES STUDIED/TREATED Under investigation for the treatment of
                          chronic diarrhea in HIV-infected people
                          [AmFAR Tx Dir 1995;7(4)]
 CLASSIFICATION CODE      Antidiarrheal [AmFAR Tx Dir 1995;7(4)]
 OTHER MAJOR USES         Antibiotic-associated diarrhea;
                          pseudomembranous colitis [Gastroenterology
                          1989 vol 96 no 4] [Pharm Res June 1991]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: Nonpathogenic yeast [AmFAR
                          Tx Dir 1995;7(4)]
 SUBSTANCE DELIVERY DATA  DOSAGE FORM: Capsules. [Gastroenterology
                          1989;96(4)]
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Oral. [AmFAR Tx Dir
                          1995;7(4)]
 MANUFACTURERS            Biocodex Inc
 REFERENCES               Hassett J, Meyers S, McFarland L, Mulligan
                          ME. Recurrent Clostridium difficile infection
                          in a patient with selective IgG1 deficiency
                          treated with intravenous immune globulin and
                          Saccharomyces boulardii. Clin Infect Dis 1995
                          Jun;20 Suppl 2:S266-8.
 REFERENCES               McFarland LV, Surawicz CM, Greenberg RN,
                          Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox
                          JL. Prevention of beta-lactam-associated
                          diarrhea by Saccharomyces boulardii compared
                          with placebo. Am J Gastroenterol 1995
                          Mar;90(3):439-48.
 REFERENCES               Born P, Lersch C, Zimmerhackl B, Classen M.
                          [The Saccharomyces boulardii therapy of
                          HIV-associated diarrhea (letter)]. Dtsch Med
                          Wochenschr. 1993 May 21; 118(20):765.
 REFERENCES               Plein K, Hotz J. Therapeutic effects of
                          Saccharomyces boulardii on mild residual
                          symptoms in a stable phase of Crohn's disease
                          with special respect to chronic diarrhea--a
                          pilot study. Z Gastroenterol 1993
                          Feb;31(2):129-34.
 REFERENCES               Kollaritsch H, Holst H, Grobara P, Wiedermann
                          G. [Prevention of traveler's diarrhea with
                          Saccharomyces boulardii. Results of a placebo
                          controlled double-blind study]. Fortschr Med
                          1993 Mar 30;111(9):152-6.
 REFERENCES               Klein SM, Elmer GW, McFarland LV, Surawicz
                          CM, Levy RH. Recovery and elimination of the
                          biotherapeutic agent, Saccharomyces
                          boulardii, in healthy human volunteers. Pharm
                          Res 1993 Nov;10(11):1615-9.
 REFERENCES               Buts JP, Corthier G, Delmee M. Saccharomyces
                          boulardii for Clostridium
                          difficile-associated enteropathies in
                          infants. J Pediatr Gastroenterol Nutr 1993
                          May;16(4):419-25.
 REFERENCES               Pothoulakis C, Kelly CP, Joshi MA, Gao N,
                          O'Keane CJ, Castagliuolo I, Lamont JT.
                          Saccharomyces boulardii inhibits Clostridium
                          difficile toxin A binding and enterotoxicity
                          in rat ileum. Gastroenterology 1993
                          Apr;104(4):1108-15.
 REFERENCES               Saint-Marc T, Sellem C, Rosello L, Touraine
                          JL.  Treatment of chronic diarrhea with
                          Saccharomyces boulardii.  Int Conf AIDS.
                          1990 Jun 20-23;6(1):212 (abstract no. Th.B.
                          363).
 ENTRY MONTH              9210
 LAST REVISION DATE       960307
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
